{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T05:12:06Z","timestamp":1773897126217,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T00:00:00Z","timestamp":1574985600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T00:00:00Z","timestamp":1574985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015652","name":"Barts Charity","doi-asserted-by":"crossref","award":["421\/2301"],"award-info":[{"award-number":["421\/2301"]}],"id":[{"id":"10.13039\/100015652","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The identification and treatment of LTBI is a key component of the WHO\u2019s strategy to eliminate TB. Recent migrants from high TB-incidence countries are recognised to be at risk TB reactivation, and many high-income countries have focused on LTBI screening and treatment programmes for this group. However, migrants are the group least likely to complete the LTBI cascade-of-care. This pragmatic cluster-randomised, parallel group, superiority trial investigates whether a model of care based entirely within a community setting (primary care) will improve treatment completion compared with treatment in specialist TB services (secondary care).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>The CATAPuLT trial (Completion and Acceptability of Treatment Across Primary Care and the community for Latent Tuberculosis) randomised 34 general practices in London, England, to evaluate the efficacy and safety of treatment for LBTI in recent migrants within primary care. GP practices were randomised to either provide management for LTBI entirely within primary care (GPs and community pharmacists) or to refer patients to secondary care. The target recruitment number for individuals is 576. The primary outcome is treatment completion (defined as taking at least 90% of antibiotic doses). The secondary outcomes assess adherence, acceptance of treatment, the incidence of adverse effects including drug-induced liver injury, the rates of active TB, patient satisfaction and cost-effectiveness of LTBI treatment. This protocol adheres to the SPIRIT Checklist.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Discussion<\/jats:title>\n<jats:p>The CATAPuLT trial seeks to provide implementation research evidence for a patient-centred intervention to improve treatment completion for LTBI amongst recent migrants to the UK.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Trial registration<\/jats:title>\n<jats:p>NCT03069807, March 2017, registered retrospectively.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12889-019-7983-7","type":"journal-article","created":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T17:02:44Z","timestamp":1575046964000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Protocol for a cluster randomised control trial evaluating the efficacy and safety of treatment for latent tuberculosis infection in recent migrants within primary care: the CATAPuLT trial"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2873-5917","authenticated-orcid":false,"given":"M.","family":"Burman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Copas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Zenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Hickson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Gosce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Trathen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Ashcroft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. R.","family":"Martineau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Abubakar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Kunst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,29]]},"reference":[{"key":"7983_CR1","unstructured":"Global Tuberculosis Report 2018. World Health Organization 2018. http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/274453\/9789241565646-eng.pdf?ua=1. Accessed 06 July 2019."},{"issue":"4","key":"7983_CR2","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1183\/09031936.00214014","volume":"45","author":"K L\u00f6nnroth","year":"2015","unstructured":"L\u00f6nnroth K, Migliori GB, Abubakar I, D'Ambrosio L, de Vries G, Diel R, Douglas P, Falzon D, Gaudreau M-A, Goletti D, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J. 2015;45(4):928\u201352.","journal-title":"Eur Respir J"},{"issue":"10","key":"7983_CR3","doi-asserted-by":"publisher","first-page":"e1002152","DOI":"10.1371\/journal.pmed.1002152","volume":"13","author":"RMGJ Houben","year":"2016","unstructured":"Houben RMGJ, Dodd PJ. The global burden of Latent tuberculosis infection: a re-estimation using mathematical Modelling. PLoS Med. 2016;13(10):e1002152\u201313.","journal-title":"PLoS Med"},{"issue":"1","key":"7983_CR4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1146\/annurev-publhealth-031912-114431","volume":"34","author":"C Dye","year":"2013","unstructured":"Dye C, Glaziou P, Floyd K, Raviglione M. Prospects for tuberculosis elimination. Annu Rev Public Health. 2013;34(1):271\u201386.","journal-title":"Annu Rev Public Health"},{"issue":"10","key":"7983_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1473-3099(18)30355-4","volume":"18","author":"I Abubakar","year":"2018","unstructured":"Abubakar I, Drobniewski F, Southern J, Sitch AJ, Jackson C, Lipman M, Deeks JJ, Griffiths C, Bothamley G, Lynn W, et al. Prognostic value of interferon-\u03b3 release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study. Lancet Infect Dis. 2018;18(10):1\u201314.","journal-title":"Lancet Infect Dis"},{"key":"7983_CR6","unstructured":"Collaborative Tuberculosis Strategy for England 2015 to 2020. Public Health England\/NHS England. 2015. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/403231\/Collaborative_TB_Strategy_for_England_2015_2020_.pdf. Accessed 04 Apr 2017."},{"issue":"11","key":"7983_CR7","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S1473-3099(16)30216-X","volume":"16","author":"Hannah Alsdurf","year":"2016","unstructured":"Alsdurf H, Hill PC, Matteelli A, Getahun H, Menzies D. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16(11):1269\u201378.","journal-title":"The Lancet Infectious Diseases"},{"issue":"1","key":"7983_CR8","doi-asserted-by":"publisher","first-page":"1701226","DOI":"10.1183\/13993003.01226-2017","volume":"51","author":"MG Loutet","year":"2018","unstructured":"Loutet MG, Burman M, Jayasekera N, Trathen D, Dart S, Kunst H, Zenner D. National roll-out of latent tuberculosis testing and treatment for new migrants in England: a retrospective evaluation in a high-incidence area. Eur Respir J. 2018;51(1):1701226.","journal-title":"Eur Respir J"},{"key":"7983_CR9","unstructured":"Latent TB Testing and Treatment for Migrants. A practical guide for commissioners and practitioners. Public Health England. 2015. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/442192\/030615_LTBI_testing_and_treatment_for_migrants_1.pdf. Accessed 09 Mar 19."},{"issue":"jan08 15","key":"7983_CR10","doi-asserted-by":"publisher","first-page":"e7586","DOI":"10.1136\/bmj.e7586","volume":"346","author":"A-W Chan","year":"2013","unstructured":"Chan A-W, Tetzlaff JM, G\u00f8tzsche PC, Altman DG, Mann H, Berlin JA, Dickersin K, Hr\u00f3bjartsson A, Schulz KF, Parulekar WR, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346(jan08 15):e7586.","journal-title":"BMJ"},{"issue":"5","key":"7983_CR11","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1177\/1060028014522982","volume":"48","author":"E Tommelein","year":"2014","unstructured":"Tommelein E, Mehuys E, Van Tongelen I, Brusselle G, Boussery K. Accuracy of the medication adherence report scale (MARS-5) as a quantitative measure of adherence to inhalation medication in patients with COPD. Ann Pharmacother. 2014;48(5):589\u201395.","journal-title":"Ann Pharmacother"},{"issue":"9572","key":"7983_CR12","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/S0140-6736(07)60707-7","volume":"369","author":"C Griffiths","year":"2007","unstructured":"Griffiths C, Sturdy P, Brewin P, Bothamley G, Eldridge S, Martineau A, MacDonald M, Ramsay J, Tibrewal S, Levi S, et al. Educational outreach to promote screening for tuberculosis in primary care: a cluster randomised controlled trial. Lancet (London, England). 2007;369(9572):1528\u201334.","journal-title":"Lancet (London, England)"},{"key":"7983_CR13","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/S0140-6736(13)62255-2","volume":"382","author":"W Leber","year":"2013","unstructured":"Leber W, McMullen H, Marlin N, Bremner S, Santos AC, Terris-Prestholt F, Boomla K, Ashcroft R, Kerry S, Martineau A, et al. Point-of-care HIV testing in primary care and early detection of HIV (RHIVA2): a cluster randomised controlled trial. Lancet. 2013;382:S7.","journal-title":"Lancet"},{"key":"7983_CR14","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1186\/1756-0500-6-342","volume":"6","author":"K Butcher","year":"2013","unstructured":"Butcher K, Biggs B-A, Leder K, Lemoh C, O'Brien D, Marshall C. Understanding of latent tuberculosis, its treatment and treatment side effects in immigrant and refugee patients. BMC Res Notes. 2013;6:342.","journal-title":"BMC Res Notes"},{"key":"7983_CR15","doi-asserted-by":"crossref","unstructured":"Goswami ND, Gadkowski LB, Piedrahita C, Bissette D, Ahearn MA, Blain MLM, \u00d8stbye T, Saukkonen J, Stout JE. Predictors of latent tuberculosis treatment initiation and completion at a U.S. public health clinic: a prospective cohort study. BMC Public Health. 2012;12(1):468\u20138.","DOI":"10.1186\/1471-2458-12-468"},{"issue":"9","key":"7983_CR16","doi-asserted-by":"publisher","first-page":"e45913","DOI":"10.1371\/journal.pone.0045913","volume":"7","author":"I Nicolau","year":"2012","unstructured":"Nicolau I, Tian L, Menzies D, Ostiguy G, Pai M. Point-of-care urine tests for smoking status and isoniazid treatment monitoring in adult patients. PLoS One. 2012;7(9):e45913\u20131.","journal-title":"PLoS One"},{"issue":"5","key":"7983_CR17","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.rmed.2010.02.001","volume":"104","author":"RL Guerra","year":"2010","unstructured":"Guerra RL, Conde MB, Efron A, Loredo C, Bastos G, Chaisson RE, Golub JE. Point-of-care Arkansas method for measuring adherence to treatment with isoniazid. Respir Med. 2010;104(5):754\u20137.","journal-title":"Respir Med"},{"issue":"5","key":"7983_CR18","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1258\/0004563041731637","volume":"41","author":"R Whitfield","year":"2004","unstructured":"Whitfield R, Cope GF. Point-of-care test to monitor adherence to anti-tuberculous treatment. Ann Clin Biochem. 2004;41(5):411\u20133.","journal-title":"Ann Clin Biochem"},{"key":"7983_CR19","unstructured":"Latent TB infection testing and treatment programme: technical guidance and specification. Public Health England. 2019. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/801582\/LTBI_technical_specification_and_guidance.pdf. Accessed 30 May 2019."},{"key":"7983_CR20","unstructured":"Guide to the methods of technology appraisal. National Institute for Health and Care Excellence. 2013. https:\/\/www.nice.org.uk\/process\/pmg9\/resources\/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781. Accessed 01 Oct 2015."},{"key":"7983_CR21","unstructured":"NHS Reference Costs. https:\/\/improvement.nhs.uk\/resources\/reference-costs\/. Accessed 01 July 2019."},{"key":"7983_CR22","unstructured":"Tuberculosis (NICE Guildeline 33). National Institute for Health and Care Excellence. 2016. https:\/\/www.nice.org.uk\/guidance\/ng33\/resources\/tuberculosis-pdf-1837390683589. Accessed 01 July 2019."},{"issue":"10178","key":"7983_CR23","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/S0140-6736(19)30024-8","volume":"393","author":"MJA Reid","year":"2019","unstructured":"Reid MJA, Arinaminpathy N, Bloom A, Bloom BR, Boehme C, Chaisson R, Chin DP, Churchyard G, Cox H, Ditiu L, et al. Building a tuberculosis-free world: the lancet commission on tuberculosis. Lancet. 2019;393(10178):1331\u201384.","journal-title":"Lancet"},{"issue":"8","key":"7983_CR24","doi-asserted-by":"publisher","first-page":"835","DOI":"10.5588\/ijtld.17.0503","volume":"22","author":"PB Shete","year":"2018","unstructured":"Shete PB, Boccia D, Dhavan P, Gebreselassie N, Lonnroth K, Marks S, Matteelli A, Posey DL, van der Werf MJ, Winston CA, et al. Defining a migrant-inclusive tuberculosis research agenda to end TB. Int J Tuberc Lung Dis. 2018;22(8):835\u201343.","journal-title":"Int J Tuberc Lung Dis"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-019-7983-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12889-019-7983-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-019-7983-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T00:12:43Z","timestamp":1606522363000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-019-7983-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,29]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["7983"],"URL":"https:\/\/doi.org\/10.1186\/s12889-019-7983-7","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,29]]},"assertion":[{"value":"1 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval for the trial was obtained from the Camden & Kings Cross Research Ethics Committee (16\/LO\/0328). Valid implied consent is assumed for participation in the trial. Eligible patients are asked for verbal consent to access their data which is in their electronic patient records.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1598"}}